TimeTeller from Hamburg is developing a saliva test that can be used to determine the optimal time for chemotherapy, based on the finding that everyone's internal clock has a significant influence on whether and how a treatment works. The startup needs up to 4 million euros for further development and extensive testing. The success at Female StartAperitivo organised by the Hamburg Investors Network HIN may help to achieve this goal.
TimeTeller is a spin-off of Charité Universitätsmedizin Berlin and the BIH Digital Health Accelerator Program and builds upon the research of the Circadian Medicine and Systems Biology research group lead by Angela Relógio. In March 2023, TimeTeller was founded as a GmbH by Angela Relógio, the technology transfer partner of Charité, Ascenion GmbH and Benjamin Dose, project manager.
Further information:
Press release by Startup City Hamburg
TimeTeller's Website
